Funded Biotechnology Startups in Brooklyn
Brooklyn biotech funding in the 16 most recent entries is dominated by one outlier: OpenTrons’ Series C closed on 2021-09-23 for $200M, which dwarfs the ne…
Brooklyn biotech funding in the 16 most recent entries is dominated by one outlier: OpenTrons’ Series C closed on 2021-09-23 for $200M, which dwarfs the next-largest disclosed round of $25M (Kingdom Supercultures on 2021-10-05). Aside from that, disclosed rounds cluster in the mid-teens to single digits, with several $2M–$8M rounds including Patina ($2M on 2026-05-21), Epi One ($2M on 2024-12-05), Xylyx Bio ($3M on 2024-09-16), and Caladan Bio ($5M on 2024-02-13).
The stage mix is also uneven: “Series Unknown” appears in 5 of 16 entries (Cresilon, Epi One, Xylyx Bio, Caladan Bio, and others with blank stage labels), while explicitly labeled rounds span Seed through Series C (e.g., Fesarius Therapeutics’ Series A on 2026-06-10 for $20M; Patina’s Seed on 2026-05-21 for $2M). Temporally, the shown rounds extend from 2021-09-23 through 2026-06-10, and there’s a notable concentration in early 2024, where multiple disclosed rounds land in March–April 2024 (e.g., First Wave BioPharma $4M on 2024-03-04, Auxilius $10M on 2024-03-15).
Most recent rounds
16 shownRelated listings
Frequently asked
Which round is the largest in this Brooklyn biotech list, and how far above the rest is it?
OpenTrons’ $200M Series C on 2021-09-23 is the only disclosed round in this set that sits far above the others; the next-largest disclosed amount is $25M from Kingdom Supercultures on 2021-10-05.
Are there any tight time clusters among the most recent rounds shown?
Yes. Early 2024 shows multiple entries in a short window: First Wave BioPharma closed on 2024-03-04 for $4M, Auxilius on 2024-03-15 for $10M, and Caladan Bio on 2024-02-13 for $5M, all within about a month.
How much of the list is missing a clear stage label versus having a stated round type?
5 of 16 entries carry a “Series Unknown” classification (Cresilon on 2025-09-08 for $17M; Epi One on 2024-12-05 for $2M; Xylyx Bio on 2024-09-16 for $3M; Caladan Bio on 2024-02-13 for $5M; and one other listed as “Series Unknown”). In addition, Auxilius and First Wave BioPharma list a blank stage field while still disclosing amounts.
Which stage types appear most clearly, and where do the largest disclosed examples show up?
Seed and Series A appear multiple times with distinct sizing: Patina’s Seed is $2M on 2026-05-21 and Barnwell Bio’s Seed is $6M on 2026-01-26, while the largest labeled non-outlier round is Fesarius Therapeutics’ Series A at $20M on 2026-06-10. Meanwhile, the largest overall labeled round is Series C (OpenTrons at $200M on 2021-09-23).
Are there small-round outliers worth focusing on, or is the distribution broadly similar?
There are small outliers at the low end: the smallest disclosed amount in the list is $500K for Girihlet on 2022-03-09, and two additional low points are $2M rounds for Patina (2026-05-21) and Epi One (2024-12-05). Those sit well below several mid-range rounds like AlgiKnit’s $13M (2022-06-29) and Kinnos’ $15M (2023-05-02).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.